On August 30, 2018 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported its participation at the H.C. Wainwright 20th Annual Global Investment Conference (Press release, Kura Oncology, AUG 30, 2018, http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-present-hc-wainwright-global-investment-conference [SID1234529214]). Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Thursday, September 6, 2018 at 9:10 a.m. ET / 6:10 a.m. PT. The conference will be held from September 4-6, 2018 in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.